131 related articles for article (PubMed ID: 38078453)
1. Comparison of teneligliptin and other gliptin-based regimens in addressing insulin resistance and glycemic control in type 2 diabetic patients: a cross-sectional study.
Singh H; Rohilla R; Jaswal S; Singla M
Expert Rev Endocrinol Metab; 2024; 19(1):81-87. PubMed ID: 38078453
[TBL] [Abstract][Full Text] [Related]
2. Teneligliptin, a Chemotype Prolyl-Thiazolidine-Based Novel Dipeptidyl Peptidase-4 Inhibitor with Insulin Sensitizing Properties.
Kutoh E; Wada A; Terayama S
Clin Drug Investig; 2016 Oct; 36(10):809-18. PubMed ID: 27352309
[TBL] [Abstract][Full Text] [Related]
3. A ProspectIve, OpeN-Label, Randomized Study Comparing EffIcacy and Safety of Teneligliptin VErsus Sitagliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: INSITES Study.
Mohan V; Ramu M; Poongothai S; Kasthuri S
J Assoc Physicians India; 2019 Oct; 67(10):14-19. PubMed ID: 31571445
[TBL] [Abstract][Full Text] [Related]
4. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
Kim Y; Kang ES; Jang HC; Kim DJ; Oh T; Kim ES; Kim NH; Choi KM; Kim SR; You J; Kim SJ; Lee MK
Diabetes Obes Metab; 2019 Mar; 21(3):631-639. PubMed ID: 30362280
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of teneligliptin, a dipeptidyl peptidase-4 inhibitor, combined with metformin in Korean patients with type 2 diabetes mellitus: a 16-week, randomized, double-blind, placebo-controlled phase III trial.
Kim MK; Rhee EJ; Han KA; Woo AC; Lee MK; Ku BJ; Chung CH; Kim KA; Lee HW; Park IB; Park JY; Chul Jang HC; Park KS; Jang WI; Cha BY
Diabetes Obes Metab; 2015 Mar; 17(3):309-12. PubMed ID: 25475929
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
7. Teneligliptin improves glycemic control with the reduction of postprandial insulin requirement in Japanese diabetic patients.
Tsuchimochi W; Ueno H; Yamashita E; Tsubouchi C; Sakoda H; Nakamura S; Nakazato M
Endocr J; 2015; 62(1):13-20. PubMed ID: 25252844
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double-blind, placebo-controlled study.
Ji L; Li L; Ma J; Li X; Li D; Meng B; Lu W; Sun J; Liu Y; Takayanagi G; Wang Y
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00222. PubMed ID: 33855222
[TBL] [Abstract][Full Text] [Related]
9. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.
Hong S; Park CY; Han KA; Chung CH; Ku BJ; Jang HC; Ahn CW; Lee MK; Moon MK; Son HS; Lee CB; Cho YW; Park SW
Diabetes Obes Metab; 2016 May; 18(5):528-32. PubMed ID: 26749529
[TBL] [Abstract][Full Text] [Related]
11. Finding the most cost-effective option from commonly used Dipeptidyl peptidase-4 inhibitors in India: a systematic study.
Singh H; Arora E; Narula S; Singla M; Otaal A; Sharma J
Expert Rev Endocrinol Metab; 2023; 18(4):347-354. PubMed ID: 37232153
[TBL] [Abstract][Full Text] [Related]
12. Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients.
Kadowaki T; Haneda M; Ito H; Sasaki K; Hiraide S; Matsukawa M; Ueno M
Adv Ther; 2018 Jun; 35(6):817-831. PubMed ID: 29777520
[TBL] [Abstract][Full Text] [Related]
13. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.
Ba J; Han P; Yuan G; Mo Z; Pan C; Wu F; Xu L; Hanson ME; Engel SS; Shankar RR
J Diabetes; 2017 Jul; 9(7):667-676. PubMed ID: 27502307
[TBL] [Abstract][Full Text] [Related]
15. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus.
Bermúdez-Pirela VJ; Cano C; Medina MT; Souki A; Lemus MA; Leal EM; Seyfi HA; Cano R; Ciscek A; Bermúdez-Arias F; Contreras F; Israili ZH; Hernández-Hernández R; Valasco M
Am J Ther; 2007; 14(2):194-202. PubMed ID: 17414590
[TBL] [Abstract][Full Text] [Related]
16. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.
Kutoh E; Kuto AN; Akiyama M; Ozawa E; Kurihara R
Eur J Clin Pharmacol; 2023 Jul; 79(7):947-959. PubMed ID: 37193913
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and Safety of Adding Basal Insulin Glargine in Patients with Type 2 Diabetes Mellitus Exhibiting Inadequate Response to Metformin and DPP-4 Inhibitors with or without Sulfonylurea.
Kang YM; Jung CH; Lee SH; Kim SW; Song KH; Kim SG; Kim JH; Cho YM; Park TS; Ku BJ; Koh G; Kim DM; Lee BW; Park JY
Diabetes Metab J; 2019 Aug; 43(4):432-446. PubMed ID: 31237133
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
19. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
Tanaka S; Suzuki K; Aoki C; Niitani M; Kato K; Tomotsune T; Aso Y
Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Charbonnel B; Karasik A; Liu J; Wu M; Meininger G;
Diabetes Care; 2006 Dec; 29(12):2638-43. PubMed ID: 17130197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
